Alyn H. Morice
Hull York Medical School
AirwayInternal medicinePathologyRandomized controlled trialIntensive care medicinePhysical therapyPlaceboAsthmaCOPDExacerbationChronic coughPopulationIn patientCough reflexAnesthesiaRefluxRespiratory systemClinical trialMedicineGastroenterology
Publications 290
#1Ji Hyang Lee (UOU: University of Ulsan)H-Index: 11
#2Woo-Jung Song (UOU: University of Ulsan)H-Index: 26
Last. Alyn H. Morice (Hull York Medical School)H-Index: 35
view all 4 authors...
There are possibilities and obstacles to the use of objective cough monitoring in real-world practice. Advances in technology will overcome the difficulties and continuous real-time cough monitoring will then provide a valuable tool in cough management.
#1Valerie J. Ludbrook (GSK: GlaxoSmithKline)H-Index: 7
#2Kate E. Hanrott (GSK: GlaxoSmithKline)H-Index: 1
Last. Lorcan McGarvey ('QUB': Queen's University Belfast)H-Index: 54
view all 13 authors...
Objective null Airway sensory nerves involved in the cough reflex are activated by adenosine triphosphate (ATP) agonism of P2X purinoceptor 3 (P2X3) receptors. Transient receptor potential vanilloid 4 (TRPV4) channel activation causes ATP release from airway cells and it is hypothesised that a TRPV4-ATP-P2X3 axis contributes to chronic cough. An adaptive study was run to determine if TRPV4 inhibition, using the selective TRPV4 channel blocker GSK2798745, was effective in reducing cough. null Met...
1 CitationsSource
#1Alyn H. Morice (University of Hull)H-Index: 35
#2Jaclyn A. Smith (MAHSC: Manchester Academic Health Science Centre)H-Index: 49
Last. Christian Friedrich (Bayer)H-Index: 11
view all 12 authors...
ATP acting via P2X3 receptors is an important mediator of refractory chronic cough (RCC). This phase 2a double-blinded crossover study assessed the safety, tolerability and efficacy of eliapixant (BAY 1817080), a selective P2X3 receptor antagonist, in adults with RCC attending specialist centres.In period A, patients received placebo for 2 weeks then eliapixant 10 mg for 1 week. In period B, patients received eliapixant 50, 200 and 750 mg twice daily for 1 week per dose level. Patients were rand...
1 CitationsSource
#1Alyn H. Morice (Hull York Medical School)H-Index: 35
#2Surinder S. Birring ('KCL': King's College London)H-Index: 53
Last. Mandel R. SherH-Index: 2
view all 10 authors...
PURPOSE This analysis assesses clinical characteristics of patients with refractory chronic cough (RCC) or unexplained chronic cough (UCC) enrolled in a phase 2 study to better understand this patient population. METHODS Patients with RCC/UCC lasting for ≥ 1 year and cough severity visual analog scale (VAS) score of > 40 mm at screening were eligible. Demographics, clinical characteristics, and medical history were collected at baseline. Cough-related measures included cough severity VAS, Cough ...
5 CitationsSource
#1Michael G. Crooks (Hull York Medical School)H-Index: 12
#2Albertus C. den Brinker (Philips)H-Index: 12
Last. Alyn H. Morice (Hull York Medical School)H-Index: 35
view all 6 authors...
INTRODUCTION Acute exacerbations of COPD (AE-COPD) are a leading cause of health service utilisation and are associated with morbidity and mortality. Identifying the prodrome of AE-COPD by monitoring symptoms and physiological parameters (telemonitoring) has proven disappointing and false alerts limit clinical utility. We report objective monitoring of cough counts around AE-COPD and the performance of a novel alert system identifying meaningful change in cough frequency. METHODS This prospectiv...
#1Alyn H. Morice (Castle Hill Hospital)H-Index: 35
Opinions differ as to when to escalate ventilatory support to intubation and mechanical ventilation
1 CitationsSource
#1Dominic L Sykes (Castle Hill Hospital)H-Index: 2
#2Luke Holdsworth (Castle Hill Hospital)H-Index: 2
Last. Michael G. Crooks (Castle Hill Hospital)H-Index: 12
view all 6 authors...
The enduring impact of COVID-19 on patients has been examined in recent studies, leading to the description of Long-COVID. We report the lasting symptom burden of COVID-19 patients from the first wave of the pandemic. All patients with COVID-19 pneumonia discharged from a large teaching hospital trust were offered follow-up. We assessed symptom burden at follow-up using a standardised data collection technique during virtual outpatient clinic appointments. Eighty-six percent of patients reported...
42 CitationsSource
#1Lorcan McGarveyH-Index: 54
#2Alyn H. MoriceH-Index: 35
Last. Jonathan SchelfhoutH-Index: 3
view all 6 authors...
Introduction The patient perspective of chronic cough (CC) diagnosis and treatment path is not well-documented. Aim To describe patient-reported diagnosis and treatment patterns among UK adults with CC. Methods An ethics-approved CC survey was administered to 2018 National Health and Wellness Survey respondents who reported coughing daily for ≥8 weeks. CC survey respondents had active CC and were excluded if they smoked/vaped in the past year or were prescribed oral corticosteroids or ACE inhibi...
#1S Thackray-Nocera (University of Hull)
Last. Simon P. HartH-Index: 26
view all 10 authors...
Introduction and Objectives Cough is a distressing symptom for some patients with pulmonary sarcoidosis. Long term treatment with azithromycin may improve cough. We aimed to assess potential efficacy of azithromycin in patients with pulmonary sarcoidosis with self-reported cough. Methods We did a non-controlled, single arm, open label clinical trial of azithromycin 250 mg once daily for 3 months in patients with pulmonary sarcoidosis who reported a chronic cough. The primary outcome was 24-hour ...